Allos Therapeutics (ALTH) Dips Ahead Of FDA Decision

August 28, 2009 · Filed Under Cancer 

Allos Therapeutics (ALTH) is down almost 10% to $7 ahead of a September 2 announcement from a regulatory panel which is reviewing its cancer drug candidate pralatrexate.

There is no other news that might move the stock

Douglas A. McIntyre

Comments

Comments are closed.

    Subscribe to BioHealth Investor BioHealth Investor RSS Feed